ATE406892T1 - Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil - Google Patents
Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracilInfo
- Publication number
- ATE406892T1 ATE406892T1 AT02726710T AT02726710T ATE406892T1 AT E406892 T1 ATE406892 T1 AT E406892T1 AT 02726710 T AT02726710 T AT 02726710T AT 02726710 T AT02726710 T AT 02726710T AT E406892 T1 ATE406892 T1 AT E406892T1
- Authority
- AT
- Austria
- Prior art keywords
- gemcitabine
- uracil
- fluoro
- preparations containing
- combination preparations
- Prior art date
Links
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002949 fluorouracil Drugs 0.000 title abstract 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 2
- 229960002930 sirolimus Drugs 0.000 title abstract 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 title 1
- 229940046044 combinations of antineoplastic agent Drugs 0.000 title 1
- 229960005277 gemcitabine Drugs 0.000 title 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 229960000235 temsirolimus Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000000340 anti-metabolite Effects 0.000 abstract 1
- 229940100197 antimetabolite Drugs 0.000 abstract 1
- 239000002256 antimetabolite Substances 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940124302 mTOR inhibitor Drugs 0.000 abstract 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28238501P | 2001-04-06 | 2001-04-06 | |
| US28238801P | 2001-04-06 | 2001-04-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE406892T1 true ATE406892T1 (de) | 2008-09-15 |
Family
ID=26961412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02726710T ATE406892T1 (de) | 2001-04-06 | 2002-04-05 | Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1385551B1 (enExample) |
| JP (1) | JP2004525950A (enExample) |
| KR (1) | KR100862178B1 (enExample) |
| CN (1) | CN1309421C (enExample) |
| AT (1) | ATE406892T1 (enExample) |
| AU (1) | AU2007242958A1 (enExample) |
| BR (1) | BR0208627A (enExample) |
| CA (1) | CA2442849A1 (enExample) |
| DE (1) | DE60228699D1 (enExample) |
| EA (1) | EA010184B1 (enExample) |
| ES (1) | ES2312568T3 (enExample) |
| HU (1) | HUP0304093A3 (enExample) |
| IL (1) | IL157898A0 (enExample) |
| MX (1) | MXPA03009092A (enExample) |
| NO (1) | NO20034433L (enExample) |
| NZ (1) | NZ540047A (enExample) |
| PL (1) | PL363991A1 (enExample) |
| PT (1) | PT1385551E (enExample) |
| SG (1) | SG152906A1 (enExample) |
| SI (1) | SI1385551T1 (enExample) |
| WO (1) | WO2002080975A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002032872A1 (fr) | 2000-10-20 | 2002-04-25 | Eisai Co., Ltd. | Composes a noyau aromatique azote |
| PT2269603E (pt) | 2001-02-19 | 2015-09-09 | Novartis Ag | Tratamento de tumores da mama com um derivado de rapamicina em combinação com exemestano |
| GB0124577D0 (en) * | 2001-10-12 | 2001-12-05 | Novartis Forschungsstiftung | Novel methods |
| AU2003210787B2 (en) | 2002-02-01 | 2009-04-23 | Medinol Ltd. | Phosphorus-containing compounds & uses thereof |
| UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
| EP1683785B1 (en) | 2003-11-11 | 2013-10-16 | Eisai R&D Management Co., Ltd. | Urea derivative and process for producing the same |
| EP1732583A4 (en) * | 2004-02-26 | 2009-08-12 | Penn State Res Found | COMBINATORIES THERAPY FOR THE TREATMENT OF NEOPLASIA USING OPIOID GROWTH FACTOR RECEPTORS |
| WO2006027545A2 (en) * | 2004-09-10 | 2006-03-16 | Agency For Science, Technology And Research | Method |
| WO2006030826A1 (ja) | 2004-09-17 | 2006-03-23 | Eisai R & D Management Co., Ltd. | 医薬組成物 |
| RU2405566C9 (ru) | 2005-02-03 | 2012-04-27 | Дзе Дженерал Хоспитал Корпорейшн | Способ лечения рака, устойчивого к гефитинибу |
| JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
| PE20070763A1 (es) * | 2005-11-04 | 2007-08-08 | Wyeth Corp | COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272 |
| EP2662082A1 (en) * | 2005-11-14 | 2013-11-13 | Ariad Pharmaceuticals, Incorporated | Administration of mTOR inhibitors |
| GB0523658D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| AU2006314444C1 (en) * | 2005-11-21 | 2018-01-04 | Novartis Ag | Neuroendocrine tumor treatment using mTOR inhibitors |
| EP1880723A1 (en) * | 2006-07-14 | 2008-01-23 | Novartis AG | Combination of mTOR inhibitor and antifolate compound |
| AU2007204410A1 (en) * | 2006-01-12 | 2007-07-19 | Novartis Ag | Combination of mTOR inhibitor and antipolate compound |
| WO2007106503A2 (en) | 2006-03-13 | 2007-09-20 | Osi Pharmaceuticals, Inc. | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors |
| CN101415409B (zh) * | 2006-04-05 | 2012-12-05 | 诺瓦提斯公司 | 用于治疗癌症的治疗剂的组合 |
| CA2652442C (en) | 2006-05-18 | 2014-12-09 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
| EP2032168A4 (en) * | 2006-06-02 | 2010-12-29 | Ariad Pharma Inc | COMBINED THERAPY BASED ON CAPECITABINE |
| EP2054061A4 (en) * | 2006-08-02 | 2009-09-02 | Ariad Pharma Inc | COMBINATION THERAPY |
| KR101472600B1 (ko) | 2006-08-28 | 2014-12-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암에 대한 항종양제 |
| WO2008044068A2 (en) * | 2006-10-11 | 2008-04-17 | Fusion Antibodies Limited | Combination therapy |
| EP2094241A4 (en) | 2006-11-14 | 2013-04-17 | Ariad Pharma Inc | ORAL FORMULATIONS |
| KR20090108086A (ko) | 2007-01-19 | 2009-10-14 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 췌장암 치료용 조성물 |
| CN101600694A (zh) | 2007-01-29 | 2009-12-09 | 卫材R&D管理有限公司 | 未分化型胃癌治疗用组合物 |
| CA3201293A1 (en) * | 2007-03-07 | 2008-09-12 | Abraxis Bioscience, Llc | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| AU2008260447B2 (en) | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| WO2009060945A1 (ja) | 2007-11-09 | 2009-05-14 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質と抗腫瘍性白金錯体との併用 |
| AU2009225434B2 (en) | 2008-03-21 | 2014-05-22 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
| DK2310011T3 (da) | 2008-06-17 | 2013-10-14 | Wyeth Llc | Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin |
| SG10202102855RA (en) | 2008-08-04 | 2021-05-28 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
| JP5992325B2 (ja) | 2009-04-06 | 2016-09-14 | ワイス・エルエルシー | 乳癌のための、ネラチニブを活用する治療計画 |
| CA2802644C (en) | 2010-06-25 | 2017-02-21 | Eisai R & D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| CA2828946C (en) | 2011-04-18 | 2016-06-21 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
| US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| MX2015004979A (es) | 2012-12-21 | 2015-07-17 | Eisai R&D Man Co Ltd | Forma amorfa de derivado de quinolina y metodo para su produccion. |
| SG11201509278XA (en) | 2013-05-14 | 2015-12-30 | Eisai R&D Man Co Ltd | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| IL302218B2 (en) | 2014-08-28 | 2024-10-01 | Eisai R&D Man Co Ltd | Methods for manufacturing high-purity lenvatinib and its derivatives |
| JP6792546B2 (ja) | 2015-02-25 | 2020-11-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体の苦味抑制方法 |
| AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
| EP3311841B1 (en) | 2015-06-16 | 2021-07-28 | PRISM BioLab Co., Ltd. | Anticancer agent |
| CN108135894B (zh) | 2015-08-20 | 2021-02-19 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| WO2017172596A1 (en) | 2016-03-28 | 2017-10-05 | Incyte Corporation | Pyrrolotriazine compounds as tam inhibitors |
| RU2750539C2 (ru) | 2017-02-08 | 2021-06-29 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Фармацевтическая композиция для лечения опухоли |
| AU2018269996A1 (en) | 2017-05-16 | 2019-11-21 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| CA3077308A1 (en) | 2017-09-27 | 2019-04-04 | Incyte Corporation | Salts of pyrrolotriazine derivatives useful as tam inhibitors |
| PL3813800T3 (pl) | 2018-06-29 | 2025-08-18 | Incyte Corporation | Formulacje inhibitora axl/mer |
| AU2021230385A1 (en) | 2020-03-06 | 2022-09-22 | Incyte Corporation | Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE877700A (fr) * | 1978-11-03 | 1980-01-14 | Ayerst Mckenna & Harrison | Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes |
| US5066493A (en) * | 1978-11-03 | 1991-11-19 | American Home Products Corporation | Rapamycin in treatment of tumors |
| US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| ATE236188T1 (de) * | 1997-01-24 | 2003-04-15 | Conpharma As | Gemcitabin-derivate |
| TW466112B (en) * | 1998-04-14 | 2001-12-01 | Lilly Co Eli | Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same |
-
2002
- 2002-04-05 PL PL02363991A patent/PL363991A1/xx unknown
- 2002-04-05 SI SI200230737T patent/SI1385551T1/sl unknown
- 2002-04-05 CN CNB028077490A patent/CN1309421C/zh not_active Expired - Fee Related
- 2002-04-05 WO PCT/US2002/010912 patent/WO2002080975A1/en not_active Ceased
- 2002-04-05 CA CA002442849A patent/CA2442849A1/en not_active Withdrawn
- 2002-04-05 AT AT02726710T patent/ATE406892T1/de not_active IP Right Cessation
- 2002-04-05 DE DE60228699T patent/DE60228699D1/de not_active Expired - Fee Related
- 2002-04-05 ES ES02726710T patent/ES2312568T3/es not_active Expired - Lifetime
- 2002-04-05 IL IL15789802A patent/IL157898A0/xx unknown
- 2002-04-05 PT PT02726710T patent/PT1385551E/pt unknown
- 2002-04-05 KR KR1020037013090A patent/KR100862178B1/ko not_active Expired - Fee Related
- 2002-04-05 HU HU0304093A patent/HUP0304093A3/hu unknown
- 2002-04-05 NZ NZ540047A patent/NZ540047A/en unknown
- 2002-04-05 JP JP2002579013A patent/JP2004525950A/ja active Pending
- 2002-04-05 MX MXPA03009092A patent/MXPA03009092A/es active IP Right Grant
- 2002-04-05 EP EP02726710A patent/EP1385551B1/en not_active Expired - Lifetime
- 2002-04-05 BR BR0208627-1A patent/BR0208627A/pt not_active IP Right Cessation
- 2002-04-05 EA EA200301091A patent/EA010184B1/ru not_active IP Right Cessation
- 2002-04-05 SG SG200506382-1A patent/SG152906A1/en unknown
-
2003
- 2003-10-03 NO NO20034433A patent/NO20034433L/no not_active Application Discontinuation
-
2007
- 2007-12-13 AU AU2007242958A patent/AU2007242958A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2442849A1 (en) | 2002-10-17 |
| DE60228699D1 (de) | 2008-10-16 |
| BR0208627A (pt) | 2004-03-09 |
| HK1060062A1 (en) | 2004-07-30 |
| KR20040007491A (ko) | 2004-01-24 |
| PL363991A1 (en) | 2004-11-29 |
| NZ540047A (en) | 2007-01-26 |
| CN1309421C (zh) | 2007-04-11 |
| NO20034433L (no) | 2003-11-25 |
| IL157898A0 (en) | 2004-03-28 |
| SG152906A1 (en) | 2009-06-29 |
| EA200301091A1 (ru) | 2004-02-26 |
| JP2004525950A (ja) | 2004-08-26 |
| EA010184B1 (ru) | 2008-06-30 |
| PT1385551E (pt) | 2008-11-03 |
| MXPA03009092A (es) | 2004-02-12 |
| CN1545419A (zh) | 2004-11-10 |
| WO2002080975A1 (en) | 2002-10-17 |
| SI1385551T1 (sl) | 2008-12-31 |
| EP1385551B1 (en) | 2008-09-03 |
| ES2312568T3 (es) | 2009-03-01 |
| NO20034433D0 (no) | 2003-10-03 |
| AU2007242958A1 (en) | 2008-01-10 |
| HUP0304093A3 (en) | 2008-08-28 |
| KR100862178B1 (ko) | 2008-10-09 |
| HUP0304093A2 (hu) | 2004-04-28 |
| EP1385551A1 (en) | 2004-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE406892T1 (de) | Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil | |
| CY1104983T1 (el) | Αντινεοπλασματικοι συνδυασμοι | |
| NO20054133L (no) | Antineoplastiske kombinasjoner omfattende at rapamycin derivat og en aromatase inhibitor | |
| DE60226666D1 (de) | Wälz- und Gleitlagerbauteil und Wälzlager | |
| ATE414514T1 (de) | Kombinationen, ein antidiarrhoikum und epothilon oder ein epothilonderivat enthaltend | |
| CY2007019I2 (el) | Β-αμινο-τετραϋδροϊμιδαζο-(1,2-α)-πυραζινες και τετραϋδροτριαζολο-(4,3-α)-πυραζινες ως αναστολεις της διπεπτιδυλο πεπτιδασης για την αγωγη ή προληψη του διαβητη | |
| NO20052855D0 (no) | Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav. | |
| FR2840523B1 (fr) | Article multicouche absorbant et recurant | |
| DE602004023760D1 (de) | Kompositstent mit inneren und äusseren stentelementen und anwendungsverfahren | |
| SG148031A1 (en) | Use of cci-779 as an antineoplastic agent | |
| IS7735A (is) | Bensódíasepín afleiður og lyfjasamsetningar sem innihalda þær. | |
| CY1109119T1 (el) | Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης που περιλαμβανουν λαμοτριγινη | |
| DE60328677D1 (de) | Stent und stent-prothese | |
| BR0301985B1 (pt) | copolímero de flúor, artigo e laminado | |
| DE50304776D1 (de) | Bohrlochbehandlungsmittel mit niedrig-toxischer ölphase | |
| BRPI0508451A (pt) | método de tratamento de linfoma não-hodgkin em um mamìfero, usos de uma combinação de cci-779 e rituximab e de uma combinação de um inibidor de mtor e rituximab, produtos contendo cci-779 e rituximab e um inibidor mtor e rituximab, embalagem farmacêutica, e, composição farmacêutica | |
| PT1228028E (pt) | Sais de hidroxieicosatetraeniato, composicoes e metodos para utilizacao no tratamento de perturbacoes da secura ocular | |
| EP1476419A4 (en) | N-BIPHENYLMETHYLAMINOCYCLOALKANCARBOXAMID-DERIVATIVE | |
| FR2849769B1 (fr) | Implant et prothese articulaire le comprenant | |
| AR033012A1 (es) | Combinaciones antineoplasicas | |
| BR0208566B1 (pt) | Derivados de Beta-Carbolina, Seu Uso, e composição Farmacêutica | |
| ECSP055823A (es) | DERIVADOS DE [6,7-DIHIDRO-5H-IMIDAZO[1,2-a]IMIDAZOL-3-SULFONILAMINO]-PROPIONAMIDA | |
| EP1433187A4 (en) | Tantalum sintered body and capacitor using the sintered body | |
| ITRM20020119A1 (it) | Composizioni contenenti plgf ad uso farmaceutico e cosmetico. | |
| FI20061130L (fi) | Tuberkuloosia hoitava ja ehkäisevä aine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1385551 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |